Affiliation:
1. V. A. Nasonova Research Institute of Rheumatology
Abstract
Alfacalcidol has shown its efficacy and safety in the treatment of patients with osteoporosis (OP) during various clinical studies. The article presents data from a study conducted in real clinical practice in order to assess the relevance of alfacalcidol in the treatment of OP patients and the patients' adherence to treatment. A survey of doctors and patients with OP and low-energy fractures was conducted. Alfacalcidol was prescribed by doctors in 27 % of cases, while in 19 % – in combination with antiresorptive drugs. Among the interviewed patients with the average duration of OP 3 years, 25 % of the respondents took alfacalcidol. Adherence to treatment during the last year was 38 %. Follow-up of patients after a low-energy fracture showed that 31 % of them received alfacalcidol, among whom treatment adherence for 36 months was 50 % for monotherapy, and 21 % for combination therapy. Thus, the survey showed that in real clinical practice, alfacalcidol is widely used both in the management of patients with OP and after low-energy fractures.
Subject
Materials Chemistry,Economics and Econometrics,Media Technology,Forestry
Reference20 articles.
1. Report on the audit of the burden of osteoporosis in eight countries of the Eurasian region. https://osteoporosis-russia.ru/wp-content/uploads/2022/02/audit_osteoporosis_raop.pdf
2. Skripnikova I. A. Active metabolites of vitamin D in the treatment of osteoporosis and the prevention of fractures. Farmateka; 2015; 4 (15): 22–26. (in Russ.)
3. Belaya Z. E., Belova K. Yu., Biryukova E. V., Dedov I. I., et al. Federal clinical guidelines for diagnosis, treatment and prevention of osteoporosis. Osteoporosis and Bone Diseases. 2021; 24 (2): 4–47. (in Russ.) https://doi.org/10.14341/osteo12930
4. Nuti R., Bianchi G., Brandi M. L., et al. Superiority of alfacalcidol compared to vitamin D plus calcium in lumbar bone mineral density in postmenopausal osteoporosis. Rheumatol Int. 2006; 26 (5): 445–453. https://doi.org/10.1007/s00296–005–0073–4
5. Ringe J. D., Farahmand P., Schacht E. Alfacalcidol in men with osteoporosis: a prospective, observational, 2-year trial on 214 patients. Rheumatol Int. 2013; 33 (3): 637–643. https://doi.org/10.1007/s00296–012–2429-x